Groundbreaking FDA Approval of GSK's RSV Vaccine for High-risk Age Group

Groundbreaking FDA Approval of GSK's RSV Vaccine for High-risk Age Group

The FDA's approval of GSK's RSV vaccine for high-risk adults aged 50 to 59 is a significant milestone that will broaden the vaccine's impact. This move expands GSK's position in the competitive RSV market, challenging key players like Pfizer and Moderna. With this approval, GSK strengthens its hold in the market and secures a strategic advantage.